alfa and ribavirin alone (PR).
[1] Results were categorized according to patients' previous response to treatment. For patients in the T12PR48 arms who had relapsed previously on treatment with PR alone, SVR was achieved by 93% (27/29) of patients who received a dose reduction to ≤ 600mg and 83% (20/24) who received a ribavirin dose reduction to 800-1000mg/day, compared to 82% (73/89) who had no reduction in their ribavirin dose. For patients who were prior partial responders, SVR was achieved by 62% (8/13), 50% (1/2) and 66% (21/32) respectively and 25% (2/8), 67% (2/3) and 31% (18/59) respectively for null responders. Analyses also examined the timing of the ribavirin dose reduction and the duration of the reduction during the studies and results were supportive of the study conclusions.
[1] These data suggest that timing, duration and extent of ribavirin dose reduction did not substantially impact SVR in the telaprevir treatment arms. Since ribavirin dose reduction was the mainstay of anemia management in the telaprevir development programme, these data suggest that reducing the ribavirin dose did not impact SVR rates.
"We have seen significant advances in the treatment of HCV with the approved direct-acting antivirals (DAAs), including telaprevir which has reported high SVR rates for previously treated and treatment-naïve adults with genotype-1 chronic HCV, however we know management of side effects is still very important," said Professor Mark Sulkowski, Professor of Medicine, Johns Hopkins University School of Medicine, Baltimore. "These results demonstrate that the reduction of ribavirin to help manage treatment-related anaemia when treating with telaprevir did not compromise the chance of clearing the virus."
Ribavirin is a synthetic antiviral nucleoside analogue, co-administered with peginterferon alfa to increase the efficacy of treatment for chronic HCV.<
'/>"/>
SOURCE Janssen Pharmaceutica N.V Copyright©2010 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 7 Related medicine technology :1.
New Sub-Analysis Evaluates Outcomes Associated with Lower Intracranial Hemorrhage Rates for Pradaxa® (dabigatran etexilate mesylate) Versus Warfarin in the RE-LY® Trial2.
petMD.com Celebrates Heartworm Awareness Month with Five Heartworm Prevention Tips for Pet Owners3.
Global Fund Celebrates Efforts of Partners Chevron, The Coca-Cola Company, (RED) and PEPFAR at Capitol Hill Event4.
BioStorage Technologies Integrates Sample Preparation Services into European Operations5.
Talyst Celebrates Its 10th Anniversary6.
Elsevier Integrates its Clinical Decision Support Solutions Into PatientKeeper CPOE7.
China Sky One Medical Reiterates CEO Sick Leave and Announces Significant Middle Management Resignations8.
Mercy Jets Celebrates Heart Month With Charitable Donations9.
Soligenix Demonstrates Positive Proof of Concept with its Proprietary Vaccine Thermostabilization Technology10.
Pevions Therapeutic Candida Vaccine Generates Functional B Cell Memory in all Vaccinees11.
Boston Scientific Epic™ Stent Demonstrates Positive Clinical Outcomes in Orion Trial